Search

Your search keyword '"María Nieto-Cid"' showing total 4 results
Start Over Author "María Nieto-Cid" Topic business
4 results on '"María Nieto-Cid"'

1. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma

Author

Cristina Rivas Juesas, Montserrat Bosque, Luz Martínez Pardo, Mercedes Sánchez Mateos, Alfredo Valenzuela Soria, Miguel Tortajada, Ángel Mazón Ramos, A.M. Plaza, María Nieto Cid, Genoveva del Río Camacho, José Batlles Garrido, Esther Ballester Asensio, Antonio Nieto Garcia, Raquel Romero, Teresa Garriga-Baraut, Elena Vázquez Rodríguez, María Penín Antón, Laura Valdesoiro Navarrete, María Araceli Caballero-Rabasco, Jaime Lozano, Verónica Sanz Santiago, E. Alonso, Alejandro López Neyra, Carmen Aragón Fernández, M M Folque, Juan Navarro Morón, A. Andrés Martín, Álvaro Gimeno Díaz de Atauri, Javier Torres-Borrego, Laura Moreno-Galarraga, Andrea Freixa, and Mirella Gaboli

Subjects
severe asthma, medicine.medical_specialty, Pediatrics, Immunology, real life, Omalizumab, humanized monoclonal antibodies, adolescents, Antibodies, Monoclonal, Humanized, Anti-asthmatic Agent, 03 medical and health sciences, 0302 clinical medicine, children, Internal medicine, medicine, anti-asthmatic agents, Humans, Immunology and Allergy, Children, adolescents, anti-asthmatic agents, humanized monoclonal antibodies, observational study, omalizumab, real-life, severe asthma, Anti-Asthmatic Agents, 030212 general & internal medicine, Child, Adverse effect, Retrospective Studies, business.industry, asthmatic agents, observational study, anti&#8208, Retrospective cohort study, Asthma, Discontinuation, omalizumab, Treatment Outcome, Pulmonology, 030228 respiratory system, Severe persistent allergic asthma, Pediatrics, Perinatology and Child Health, Cohort, Observational study, business, medicine.drug
Abstract

BACKGROUND: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. METHODS: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients

Published
2021
Full Text
View/download PDF

2. Author response for 'Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma'

Author

Javier Torres Borrego, Antonio Nieto Garcia, Álvaro Gimeno Díaz de Atauri, Ana Mª Plaza Martín, María del Mar Folqué Giménez, A. Andrés Martín, Genoveva del Río Camacho, Luz Martínez Pardo, Montse Bosque García, Miguel Tortajada-Girbés, Alejandro López Neyra, Mercedes Sánchez Mateos, Jaime Lozano Blasco, Andrea Freixa, E. Alonso, Esther Ballester Asensio, Laura Moreno-Galarraga, Juan Navarro Morón, Mirella Gaboli, Carmen Aragón Fernández, Ángel Mazón Ramos, Alfredo Valenzuela Soria, Raquel García, Cristina Rivas Juesas, María Nieto Cid, Laura Valdesoiro Navarrete, Verónica Sanz Santiago, Teresa Garriga-Baraut, María Araceli Caballero-Rabasco, Elena Vázquez Rodríguez, José Batlles Garrido, and María Penín Antón

Subjects
Pediatrics, medicine.medical_specialty, business.industry, Severe persistent allergic asthma, Medicine, Omalizumab, business, medicine.drug
Published
2021
Full Text
View/download PDF

4. Bacterial immunotherapy in children with wheezing attacks: clinical impact and mechanism of action

Author

Paola Brandi, Sarai Martínez-Cano, Ángel Mazón, Laura Conejero Hall, Francisco J. Cueto, Paula Saz-Leal, Joaquín Amores-Iniesta, Michel Enamorado, David Sancho, Antonio Nieto García, Miguel Casanovas, and María Nieto Cid

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, Immunotherapy, Placebo group, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, Mechanism of action, Quality of life, Immunity, Internal medicine, Global health, Medicine, Nasal administration, 030212 general & internal medicine, medicine.symptom, business, Viral etiology
Abstract

Background: Recurrent wheezing affects one third of children being a global health problem with considerable expenditure and impact on quality of life. Virtually all wheezing attacks (WA) in young children are of viral etiology. Their prevention is a major concern as effective therapies are still lacking. Aims: To evaluate the efficacy and safety of a mucosal whole-cell inactivated polybacterial preparation (MV130) in the prevention of WA, and to investigate the underlying mechanism of action. Methods: A randomized, double-blind, placebo-controlled, parallel-group study, including 120 children Results: A reduction of 40% in the number of WA in the active vs the placebo group (p Administration of MV130 conferred protection to intranasal viral infection in mice. This non-specific resistance was mediated by trained immunity. Conclusion: We provide evidence for the first time that a mucosal (sublingual) polybacterial formulation induces trained immunity, confers broad protection beyond the pathogens included in the preparation and shows clinical efficacy against a virus-related condition such as WA, with an excelent safety profile.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results